TY - JOUR
T1 - Meningococcal disease and control in China
T2 - Findings and updates from the Global Meningococcal Initiative (GMI)
AU - Li, Junhong
AU - Shao, Zhujun
AU - Liu, Gang
AU - Bai, Xilian
AU - Borrow, Raymond
AU - Chen, Min
AU - Guo, Qinglan
AU - Han, Yue
AU - Li, Yixing
AU - Taha, Muhamed Kheir
AU - Xu, Xihai
AU - Xu, Xin
AU - Zheng, Huizhen
N1 - Publisher Copyright:
© 2018
PY - 2018/5
Y1 - 2018/5
N2 - The Global Meningococcal Initiative (GMI) is a global expert group, including scientists, clinicians and public health officials from a wide range of specialities. The goal of the GMI is to prevent meningococcal disease worldwide through education, research, and co-operation. The Chinese GMI roundtable meeting was held in June 2017. The GMI met with local experts to gain insight into the meningococcal disease burden in China and current prevention and vaccination strategies in place. China experienced five epidemics of serogroup A meningococcal disease (MenA) between 1938 and 1977, with peak incidence of 403/100,000 recorded in 1967. MenA incidence rates have significantly declined following the universal introduction of the MenA polysaccharide vaccine in China in the 1980s. Further, surveillance data indicates changing meningococcal epidemiology in China with the emergence of new clones of serogroup B from serogroup C clonal complex (cc) 4821 due to capsular switching, and the international spread of serogroup W cc11. The importance of carriage and herd protection for controlling meningococcal disease was highlighted with the view to introduce conjugate vaccines and serogroup B vaccines into the national immunization schedule. Improved disease surveillance and standardized laboratory techniques across and within provinces will ensure optimal epidemiological monitoring.
AB - The Global Meningococcal Initiative (GMI) is a global expert group, including scientists, clinicians and public health officials from a wide range of specialities. The goal of the GMI is to prevent meningococcal disease worldwide through education, research, and co-operation. The Chinese GMI roundtable meeting was held in June 2017. The GMI met with local experts to gain insight into the meningococcal disease burden in China and current prevention and vaccination strategies in place. China experienced five epidemics of serogroup A meningococcal disease (MenA) between 1938 and 1977, with peak incidence of 403/100,000 recorded in 1967. MenA incidence rates have significantly declined following the universal introduction of the MenA polysaccharide vaccine in China in the 1980s. Further, surveillance data indicates changing meningococcal epidemiology in China with the emergence of new clones of serogroup B from serogroup C clonal complex (cc) 4821 due to capsular switching, and the international spread of serogroup W cc11. The importance of carriage and herd protection for controlling meningococcal disease was highlighted with the view to introduce conjugate vaccines and serogroup B vaccines into the national immunization schedule. Improved disease surveillance and standardized laboratory techniques across and within provinces will ensure optimal epidemiological monitoring.
KW - Bacterial meningitis
KW - China
KW - Conjugate vaccine
KW - Epidemiology
KW - Immunization program
KW - Meningococcal disease
KW - Neisseria meningitidis
KW - Polysaccharide vaccine
KW - Surveillance
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85044518271&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2018.01.007
DO - 10.1016/j.jinf.2018.01.007
M3 - Review article
C2 - 29406154
AN - SCOPUS:85044518271
SN - 0163-4453
VL - 76
SP - 429
EP - 437
JO - Journal of Infection
JF - Journal of Infection
IS - 5
ER -